Get the Stockscreener App
7.31
1.95%
0.14
Satellos Bioscience Inc stock is traded at $7.31, with a volume of 20,520.
It is up +1.95% in the last 24 hours and down -8.63% over the past month.
Satellos Bioscience Inc is a Canadian biotechnology and drug development company. The company is developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. The company's program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation, which Satellos has identified as a root cause of the progressive nature of this disease.
See More
Previous Close:
$7.17
Open:
$7.14
24h Volume:
20,520
Relative Volume:
0.31
Market Cap:
$152.28M
Revenue:
-
Net Income/Loss:
$-24.87M
P/E Ratio:
-5.5383
EPS:
-1.3199
Net Cash Flow:
$-23.65M
1W Performance:
+16.96%
1M Performance:
-8.63%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$7.08
$7.46
1-Week Range:
$5.90
$7.58
52-Week Range:
$5.50
$13.39
Satellos Bioscience Inc Stock (MSLE) Company Profile
Name
Satellos Bioscience Inc
Sector
Industry
Phone
-
Address
-
Compare MSLE vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MSLE
Satellos Bioscience Inc
|
7.31 | 149.36M | 0 | -24.87M | -23.65M | -1.3199 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Satellos Bioscience Inc Stock (MSLE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-06-26 | Initiated | Leerink Partners | Outperform |
| Mar-11-26 | Initiated | Cantor Fitzgerald | Overweight |
Satellos Bioscience Inc Stock (MSLE) Latest News
MSLE : Satellos Bioscience Inc. Key Company Metrics & Non-finance Metrics - Zacks Investment Research
MSLE: Satellos Bioscience Inc.Insider Transations - Zacks Investment Research
Satellos to Present at the Bloom Burton & Co. Healthcare Investor Conference - Investing News Network
Satellos Bioscience to Showcase DMD Program at April Bloom Burton Healthcare Investor Conference - TipRanks
Satellos Bioscience (NASDAQ: MSLE) plans Bloom Burton investor conference presentation - Stock Titan
Satellos Bioscience (NASDAQ:MSLE) Coverage Initiated by Analysts at Leerink Partners - Defense World
Satellos Bioscience Inc. (NASDAQ:MSLE) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Satellos Bioscience (NASDAQ:MSLE) Now Covered by Analysts at Leerink Partners - MarketBeat
Leerink initiates Satellos Bioscience stock with Outperform rating By Investing.com - Investing.com South Africa
MSLE Archives - 24/7 Wall St.
Leerink initiates Satellos Bioscience stock with Outperform rating - Investing.com
Satellos initiated with an Outperform at Leerink - TipRanks
Investment bank Leerink Partners recently released a research report, initiating coverage on biotechnology company Satellos Bioscience Inc. (stock symbol: MSLE) for the first time. - Bitget
Satellos Bioscience Inc. (0IT.SG) Options Chain - Yahoo! Finance Canada
All News for MSLE : Satellos Bioscience Inc. - Zacks Investment Research
What date does Satellos Bioscience Inc.'s (MSLE) report EarningsEarnings Calendar & Announcement - zacks.com
Long Term Trading Analysis for (MSCL) (MSCL:CA) - Stock Traders Daily
Brokers Offer Predictions for MSLE FY2030 Earnings - Defense World
FY2030 Earnings Forecast for MSLE Issued By HC Wainwright - MarketBeat
Dividend HistorySatellos Bioscience Inc. (MSLE) - Zacks Investment Research
Satellos Bioscience: 2025 Financial Performance - AlphaStreet
Satellos Bioscience (NASDAQ:MSLE) Releases Earnings Results - MarketBeat
Stocks in play: Satellos Bioscience Inc. - Barchart
Satellos Bioscience Posts 2025 Results, Advances SAT-3247 Into Global Phase 2 Duchenne Trials - TipRanks
Satellos Bioscience Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Satellos Bioscience: Q4 Earnings Snapshot - marketscreener.com
Satellos Bioscience : Fourth Quarter 2025 Management’s Discussion Analysis - marketscreener.com
Satellos Bioscience (NASDAQ: MSLE) files annual report; 15,458,903 shares - Stock Titan
Satellos Bioscience (MSLE) funds 2027 runway while advancing Phase 2 DMD trials - Stock Titan
Satellos Reports 2025 Financial Results and Highlights Recent Company Progress - 富途牛牛
MSLE Earnings History & Surprises | EPS & Revenue Results | SATELLOS BIOSCIENCE INC (NASDAQ:MSLE) - ChartMill
MSLE News | SATELLOS BIOSCIENCE INC (NASDAQ:MSLE) - ChartMill
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Satellos Bioscience (NASDAQ:MSLE) Downgraded to "Strong Sell" Rating by Wall Street Zen - MarketBeat
Cantor Fitzgerald Initiates Coverage on Satellos Bioscience (NASDAQ:MSLE) - Defense World
(MSCL) Comprehensive Trading Strategy Report (MSCL:CA) - Stock Traders Daily
This Canadian biotech stock will beat the market, analyst says - Cantech Letter
This Ligand Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday - Benzinga
Satellos Bioscience Inc. - Mena FN
Satellos Presents Interim SAT-3247 Clinical and Biomarker Data in Duchenne Muscular Dystrophy at the 2026 MDA Clinical & Scientific Conference - Bitget
Satellos Bioscience Unveils Positive Interim SAT-3247 Data in Duchenne Muscular Dystrophy at MDA 2026 - TipRanks
Interim Duchenne and FSHD data on SAT-3247 from Satellos (NASDAQ: MSLE) - Stock Titan
(MSCL) Advanced Equity Analysis (MSCL:CA) - Stock Traders Daily
Satellos prices $50M public offering - MSN
(MSCL) Technical Analysis and Trading Signals (MSCL:CA) - Stock Traders Daily
Satellos Bioscience Inc expected to post a loss of 21 cents a shareEarnings Preview - TradingView
(MSCL) Trading Performance and Risk Management (MSCL:CA) - Stock Traders Daily
MSCLFSatellos Bioscience Inc Latest Stock News & Market Updates - Stock Titan
(MSCL) Strategic Market Analysis (MSCL:CA) - Stock Traders Daily
Satellos Bioscience (MSLE) Stock Analysis Report | Financials & Insights - Benzinga España
Duchenne Muscular Dystrophy Clinical Trial Pipeline Gains Momentum: 75+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - StreetInsider
Satellos Bioscience Inc Stock (MSLE) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):